Ivan Griffin
Founder chez BENEVOLENTAI
Profil
Ivan Griffin is the founder of BenevolentAI SA, where he holds the title of Chief Operating Officer from 2013 to present.
He was also the founder of BenevolentAI Ltd., established in 2015, where he held the title of Senior Vice President-Partnerships.
Dr. Griffin's current job is as a Director at BenevolentAI Cambridge Ltd.
Dr. Griffin's former jobs include being a Secretary & Director at Cerogenix Ltd.
from 2005 to 2007, a Director at Sirigen Group Ltd., a Principal at IP Group Plc, and an Investment Manager at Nesta Investment Management LLP from 2009 to 2014.
Dr. Griffin received his undergraduate and doctorate degrees from the University of Oxford.
Dr. Griffin is also the founder of BenevolentAI.
Postes actifs de Ivan Griffin
| Sociétés | Poste | Début |
|---|---|---|
| BENEVOLENTAI | Founder | 01/11/2013 |
BenevolentAI Cambridge Ltd.
 BenevolentAI Cambridge Ltd. Miscellaneous Commercial ServicesCommercial Services BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom. | Director/Board Member | 29/05/2019 |
Anciens postes connus de Ivan Griffin
| Sociétés | Poste | Fin |
|---|---|---|
Nesta Investment Management LLP
 Nesta Investment Management LLP Investment ManagersFinance Nesta Investment Management LLP. (NESTA Investments) subsidiary of Nesta formerly NESTA, is a venture capital firm founded in 1998. The firm is headquartered in London city United Kingdom. | Private Equity Investor | 01/01/2014 |
Cerogenix Ltd.
 Cerogenix Ltd. Miscellaneous Commercial ServicesCommercial Services Cerogenix Ltd. provides pharmaceutical research and development services. The company focuses on developing therapeutics for the treatment of neurological diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. Cerogenix was founded in September, 2005 by Adrian Pini and is located in London, UK | Director/Board Member | 24/08/2007 |
BenevolentAI Ltd.
 BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The private company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Founder | - |
Sirigen Group Ltd.
 Sirigen Group Ltd. Chemicals: Major DiversifiedProcess Industries Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality. | Director/Board Member | - |
| IP GROUP PLC | Corporate Officer/Principal | - |
Formation de Ivan Griffin
| University of Oxford | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| IP GROUP PLC | Commercial Services |
| BENEVOLENTAI | Health Technology |
| Entreprise privées | 5 |
|---|---|
BenevolentAI Cambridge Ltd.
BenevolentAI Cambridge Ltd. Miscellaneous Commercial ServicesCommercial Services BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom. | Commercial Services |
Cerogenix Ltd.
Cerogenix Ltd. Miscellaneous Commercial ServicesCommercial Services Cerogenix Ltd. provides pharmaceutical research and development services. The company focuses on developing therapeutics for the treatment of neurological diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. Cerogenix was founded in September, 2005 by Adrian Pini and is located in London, UK | Commercial Services |
Sirigen Group Ltd.
Sirigen Group Ltd. Chemicals: Major DiversifiedProcess Industries Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality. | Process Industries |
Nesta Investment Management LLP
Nesta Investment Management LLP Investment ManagersFinance Nesta Investment Management LLP. (NESTA Investments) subsidiary of Nesta formerly NESTA, is a venture capital firm founded in 1998. The firm is headquartered in London city United Kingdom. | Finance |
BenevolentAI Ltd.
BenevolentAI Ltd. Packaged SoftwareTechnology Services Part of BenevolentAI SA, BenevolentAI Ltd. develops artificial intelligence applications. The private company is based in London, UK. The British company was founded in 2015 by Kenneth Patrick Mulvany, Ivan Griffin, Michael Brennan. BenevolentAI was acquired by Odyssey Acquisition SA on April 22, 2022 for $1,087.33 million. | Technology Services |
